Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Boosted by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,303 shares of the medical research company’s stock after buying an additional 786 shares during the quarter. Kornitzer Capital Management Inc. KS owned 0.14% of Bio-Rad Laboratories worth $12,911,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Avior Wealth Management LLC boosted its stake in Bio-Rad Laboratories by 3.3% in the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after purchasing an additional 32 shares during the period. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Bio-Rad Laboratories by 3.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock valued at $296,000 after buying an additional 34 shares in the last quarter. CIBC Asset Management Inc raised its position in Bio-Rad Laboratories by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock valued at $234,000 after buying an additional 34 shares during the period. Finally, Ballentine Partners LLC lifted its stake in Bio-Rad Laboratories by 5.2% in the 4th quarter. Ballentine Partners LLC now owns 714 shares of the medical research company’s stock worth $235,000 after acquiring an additional 35 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada restated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Trading Down 9.7 %

Shares of BIO stock opened at $276.55 on Tuesday. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a market cap of $7.74 billion, a PE ratio of -10.12 and a beta of 0.90. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The business’s 50 day moving average is $337.34 and its two-hundred day moving average is $335.68.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.